Trial Profile

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-102 in Adult Patients With GPC3-Expressing Previously Treated Solid Tumors

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 04 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TAK-102 (Primary)
Indications Gastric cancer; Liposarcoma; Liver cancer; Neuroendocrine carcinoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Takeda

Most Recent Events

29 May 2025 Status changed from active, no longer recruiting to discontinued business decision unrelated to patient safety.
30 Jul 2024 Planned End Date changed from 31 Dec 2026 to 4 Jul 2026.
30 Jul 2024 Planned primary completion date changed from 31 Dec 2026 to 4 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com